)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
RAPT Therapeutics (RAPT) investor relations material
RAPT Therapeutics TD Cowen Immunology and Inflammation Summit summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen Immunology and Inflammation Summit summary13 Nov, 2025
Product innovation and differentiation
Ozureprubart (ozu) is a half-life extended anti-IgE drug, designed for less frequent dosing and improved potency compared to Xolair.
Ozu uses the same epitope as omalizumab, with a YTE mutation extending half-life from 24 to 60 days.
Dosing could be reduced to 4–6 injections per year, compared to 13–26 for Xolair.
Ozu aims to treat patients excluded from Xolair due to high weight or IgE, and reduce the need for updosing.
Patent exclusivity is expected through at least 2041.
Clinical trial results and plans
Phase II Chinese CSU study showed Q8 and Q12 week dosing of ozu matched or outperformed Xolair, with strong durability and safety.
Phase III plans include two pivotal studies, each with 300–350 patients, using UAS7 at week 12 as the primary endpoint.
FDA familiarity with the IgE mechanism and shared epitope with omalizumab may streamline approval.
Global development includes large phase III studies in China for asthma and CSU, contributing to the safety database.
Q12 week dosing is considered optimal for both clinical practice and commercial adoption.
Market landscape and unmet needs
Xolair is widely used in food allergy, especially among children, but requires frequent dosing and excludes high IgE/weight patients.
Ozu's less frequent dosing is highly preferred by patients and prescribers, especially for pediatric use.
Ozu could address 25–30% of patients currently ineligible for Xolair, aiming for a label independent of IgE and weight.
Market research indicates strong demand for Q12 week dosing.
Why is Q12 week dosing Ozu's 'sweet spot' in CSU?
How will Ozu expand food allergy patient access?
How do China studies aid Ozu's US regulatory path?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next RAPT Therapeutics earnings date
Q4 20256 Mar, 2026
Next RAPT Therapeutics earnings date
Q4 20256 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
RAPT Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in immunology-based treatments. The company's primary focus is on discovering, developing, and commercializing oral small molecule therapies for significant unmet needs in inflammatory diseases and cancer. Utilizing a proprietary drug discovery and development engine, RAPT Therapeutics designs highly selective small molecules aimed at modulating critical immune responses. The company's pipeline includes drug candidates targeting CCR4 and other key immune pathways, with ongoing development for conditions such as atopic dermatitis and various cancers. RAPT Therapeutics is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage